Gujarat Themis Biosyn shares were up 5.23% at Rs 388.0 as of 10:17 am, after the company’s regulatory disclosure triggered fresh buying interest. The stock gained Rs 19.3 from the previous close of Rs 368.7, with the session’s day range placed between Rs 377.0 and Rs 401.9.
From a technical angle, the stock continues to look strong. It is trading well above its 50-day moving average of Rs 318.18 and its 200-day moving average of Rs 369.93, which suggests that momentum remains firmly positive. The current market cap stands at about Rs 4,227.85 crore, while volume of 2.56 lakh shares indicates active participation in the counter.
Gujarat Themis Biosyn has signed a definitive agreement to acquire 100% equity stake in Japan-based MicroBiopharm Japan Co. Ltd. (MBJ) through its wholly owned subsidiary, Themis Biosyn Japan Limited.
The acquisition, valued at approximately JPY 21.5 billion (around ₹1,300 crore), is aimed at strengthening Gujarat Themis’ presence in precision fermentation, biotechnology and next-generation pharmaceutical manufacturing. MBJ is a well-established Japanese pharmaceutical company with expertise in microbial fermentation, APIs, plasmid DNA manufacturing, ADC conjugation and enzyme bioconversion platforms.
The company said the deal marks a major strategic shift from a fermentation-led intermediates business toward a high-value CDMO (Contract Development and Manufacturing Organization) platform. The transaction is expected to close in Q2 FY2027, subject to regulatory approvals in Japan and customary conditions.
MBJ reported estimated FY2026 revenue of around JPY 9.5 billion (approximately ₹570 crore), while Gujarat Themis plans to fund the acquisition through a mix of debt and equity.
Disclaimer: This article is generated for informational purposes only and does not constitute financial, investment, or trading advice. The data and analysis presented are based on publicly available market information at the time of writing. Markets are subject to risk. Please consult a qualified financial advisor before making any investment or trading decisions. Business Upturn does not accept responsibility for any losses arising from reliance on this content.